Merck's (NYSE:MRK) oncology drugs' revenue could grow at a CAGR of 10.3% from $8.24 billion in 2018 to $10.95 billion in 2021, according to Trefis estimates. This growth will likely be led by higher sales of Keytruda, as well as higher alliance revenues from Lynparaza and Lenvima. Below we discuss..
How Much Can Merck's Oncology Drugs' Revenue Grow Over The Next Three Years?
Forbes - 7 Jun 2019 22:33
Merck's (NYSE:MRK) oncology drugs' revenue could grow at a CAGR of 10.3% from $8.24 billion in 2018 to $10.95 billion in 2021, according to Trefis estimates. This growth will likely be led by higher sales of Keytruda, as well as higher alliance revenues from Lynparaza and Lenvima. Below we discuss..
Share this Article
Recommended